CD274 and neoplasm: The blocking of the PD-1/PD-L1 signaling pathway by PD-1/PD-L1 inhibitors can effectively enhance the function of T-lymphocytes, resulting in the promoting of anti-tumor immunity, suppressing of tumor immunity, and suppressing of tumor growth [6, 8].